RxDoctor Payments DataLook up a doctor →

Syed Quadri, DO

Pain Medicine · Michigan City, INNPI 1992926307

Payments from drug & device makers

$9,468in general payments, 2019–2025

Across 473 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$633
  • Medtronic$596
  • Pfizer$369
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,466100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,468 in reported general payments places this provider in the 75th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$235,992
Medicare patients
392
Services billed
3,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl24$28,400
BelbucaBuprenorphine Hcl14$8,123
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen346$7,894
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen138$4,301
Oxycodone Hcl72$2,941
Diclofenac Sodium16$1,339
Gabapentin111$1,297
Pregabalin62$1,206
Buprenorphine Hcl16$991
Tramadol Hcl121$826
Cyclobenzaprine Hcl41$321
Tizanidine Hcl29$304
Morphine Sulfate ErMorphine Sulfate11$208
Duloxetine Hcl16$177
Baclofen15$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$633$8,12314 claims
Hikma Pharmaceuticals USABuprenorphine Hcl$49$99116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →